Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsSimplyHealthcare methotrexate Prior Auth Policy | …
    Ask Trek AI about this page
    CurrentsimplyhealthcarePolicy MTX

    Step therapy for oral methotrexate products (Jylamvo, Xatmep)

    Customize your policy alerts

    Sign up for simplyhealthcare Policy MTX alerts

    Get alerted when Policy MTX changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs step therapy requirements for specified oral methotrexate products (Jylamvo and Xatmep) for Simply Healthcare Plans members. It defines required prior trial of an initial step drug before coverage of the branded/step-2 products.

    Policy Summary
    Payersimplyhealthcare
    PolicyStep therapy for oral methotrexate products (Jylamvo, Xatmep)
    Policy CodePolicy MTX
    Change TypeNo material change
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateAug 1, 2026
    Key ActionDocument a trial of the Step 1 drug (oral methotrexate sodium) before requesting authorization for Jylamvo or Xatmep.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Step therapy tiers
    2Step 2 drugs listed
    1Step 1 specified

    Coverage Criteria

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Initial Authorization for Jylamvo/Xatmep

    Covered when ALL of the following are met

    Step therapy: Patient has tried a Step 1 drug: oral methotrexate sodium.trial of Step 1 drug documented

    If trial is documented, authorization for Step 2 (Jylamvo or Xatmep) will be covered.

    No explicit exclusions for Jylamvo or Xatmep are listed in the policy text. The document specifies the step-therapy sequencing (Step 1: oral methotrexate sodium; Step 2: Jylamvo, Xatmep) but does not identify any product-level or indication-based exclusions for these Step 2 agents.

    The policy does not specify any items under a "not medically necessary" section for Jylamvo or Xatmep. Coverage is governed by the step-therapy requirement described (trial of Step 1 drug required) rather than explicit non-coverage language in the provided text.

    Products and Codes

    Products AffectedNDC
    JYLAMVO SOLUTION 2 MG/ML ORALProduct listed as affected (Jylamvo)
    XATMEP SOLUTION 2.5 MG/ML ORALProduct listed as affected (Xatmep)
    Adjacent policy example productsNDC
    febuxostat 40 mg tabletExample product listed in adjacent policy text
    febuxostat 80 mg tabletExample product listed in adjacent policy text

    Provider Actions / Authorization Requirements

    Prior Authorization

    Step therapy prior authorization required

    Authorization for Jylamvo or Xatmep requires a prior trial of the Step 1 agent oral methotrexate sodium before coverage will be approved.

    • Applies to Jylamvo (methotrexate) and Xatmep (methotrexate).
    Step Therapy

    Coverage conditional on prior Step 1 trial

    If the patient has already tried a Step 1 drug (oral methotrexate sodium), authorization for a Step 2 drug (Jylamvo or Xatmep) will be covered.

    • Step 1 Drug(s): oral methotrexate sodium.
    • Step 2 Drug(s): Jylamvo (methotrexate), Xatmep (methotrexate).
    Documentation Required

    Document prior Step 1 trial

    Provider must document a trial of the Step 1 drug (oral methotrexate sodium) as part of the authorization request for Jylamvo or Xatmep.

    • Include evidence of trial of oral methotrexate sodium in the prior authorization submission.
    Denial Risk

    Denial risk if prior trial not documented

    Failure to document a prior trial of the Step 1 drug (oral methotrexate sodium) may result in denial of authorization for Jylamvo or Xatmep.

    • Denial risk applies when trial of the Step 1 agent is not documented.

    Background

    Methotrexate is used across autoimmune and oncologic indications; within this policy the formulary places oral methotrexate sodium as the Step 1 preferred agent and designates branded oral formulations Jylamvo and Xatmep as Step 2 products. Authorization for the Step 2 agents is contingent on documentation that the member has tried the Step 1 drug.

    Definitions

    inv-11: oral methotrexate sodium — Step 1 Drug(s)
    Termoral methotrexate sodium
    Role in policyRequired Step 1 agent — member must have tried this medication before Step 2 products will be authorized.
    Documentation requirementProvider must document trial of oral methotrexate sodium to support authorization for Step 2 products.
    Relationship to coverageIf trial of oral methotrexate sodium is documented, authorization for Step 2 (Jylamvo or Xatmep) will be covered.
    inv-12: Jylamvo (methotrexate), Xatmep (methotrexate) — Step 2 Drug(s)
    ProductsJylamvo (methotrexate); Xatmep (methotrexate)
    Formulations listedJYLAMVO SOLUTION 2 MG/ML ORAL; XATMEP SOLUTION 2.5 MG/ML ORAL
    Coverage conditionAuthorization for these Step 2 products is covered when a trial of the Step 1 drug (oral methotrexate sodium) is documented.
    Policy effective dateEffective 2026-08-01

    Initial Therapy Requirement

    Initial Therapy Requirement

    Initial therapy step requirement

    Initial step requirement: Documentation of trial of Step 1 drug (oral methotrexate sodium).trial documented

    Authorization for Step 2 products (Jylamvo, Xatmep) contingent on this trial.

    Step Therapy Details

    StepRequired prior therapyStep 2 productsCoverage
    Step 1Trial of oral methotrexate sodium documentedN/A (initial preferred agent)
    Step 2Patient has tried a Step 1 drug (oral methotrexate sodium)Jylamvo (methotrexate); Xatmep (methotrexate)Authorization covered when prior trial documented
    Policy Summary
    Payersimplyhealthcare
    PolicyStep therapy for oral methotrexate products (Jylamvo, Xatmep)
    Policy CodePolicy MTX
    Change TypeNo material change
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateAug 1, 2026
    Key ActionDocument a trial of the Step 1 drug (oral methotrexate sodium) before requesting authorization for Jylamvo or Xatmep.
    SourceLink
    On This Page
    Coverage CriteriaProducts and CodesProvider Actions / Authorization RequirementsBackgroundDefinitionsInitial Therapy RequirementStep Therapy Details